Indefinite lenalidomide maintenance has long been standard care for standard-risk newly diagnosed multiple myeloma patients not undergoing stem cell transplants, despite little evidence to guide the optimal duration of treatment. The ECOG-ACRIN ENDURANCE trial, published in the New England Journal of Medicine, found more toxicity with no survival benefit from continuing maintenance beyond 2 years, providing evidence to change clinical practice.  

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

 New data on breastfeeding initiation across the U.S. reveal broad geographic patterns as well as local factors that can inform targeted public health interventions. The study by Tony Grubesic from the University of California Riverside and colleagues was published July 15, 2026, in the open-access journal PLOS Global Public Health.

BUFFALO, NY — July 15, 2026 — A new case report was published in Volume 13 of Oncoscience on May 22, 2026, titled “Cervical angioleiomyoma: A rare tumor behind persistent menorrhagia and pelvic pain.”

Texas A&M University researchers use a naturally occurring gut chemical to heal the brain after traumatic injury, making post traumatic seizures rarer and harder to trigger while pointing toward a future where epilepsy may be prevented before it begins

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on. The work, supported in part by the National Institutes of Health, was published online July 14 in the Proceedings of the National Academy of Sciences.

WashU Medicine researchers show in mice that their technique to designing medications, in which modular components of anti-cancer drugs are administered separately and assembled in the body using what's known as click chemistry, is more effective than standard treatments at targeting and shrinking tumors. 

In a new report of research, scientists at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center say they have found a potential therapeutic target that can boost the potency of a chemotherapy used to treat certain cancers.

The new findings suggest that acid-suppressing drugs already approved by the FDA could be used to treat or prevent the spread of HR+ breast cancer, the most common form of metastatic breast cancer.